Continuous Venovenous Hemofiltration Versus Conventional Treatment for Acute Severe Hypernatremia

• Status: Unknown status
• Trial end date: 2017-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The patients with severe hypernatremia who received conventional treatment are often undertreated. Continuous venovenous hemofiltration (CVVH) can effectively remove solute or water from circulation system. Several case reports demonstrated that CVVH could effectively decrease serum sodium concentration of the patients with severe hypernatremia. The use of CVVH for acute severe hypernatremia in critically ill patients could improve patient survival by effectively decreasing the serum sodium concentration to a normal level.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Air Force Military Medical University, China; Fourth Military Medical University

Criteria

Inclusion Criteria:

1. Age≥18 years

2. Acute severe hypernatremia(increasing of serum sodium levels from normal levels to ≥160 mmol/L within 48 hours)

3. ICU patients

Exclusion Criteria:

1. Hypovolemic hypernatremia fractional excretion of sodium <0.5% and Urea/Creatinine >40 receiving diuretics: Urea/Creatinine >40, No edema.

2. Acute kidney injure network III

3. End-stage renal disease Hemodialysis or peritoneal dialysis

4. K+>6.5mmol/L The drug is difficult to treat hyperkalemia

5. Hydrogen ion concentration<7.2 The drug is difficult to treat metabolic acidosis

6. Acute pulmonary edema

7. Systolic blood pressure <90 mmHg vasoactive drugs in the treatment of systolic blood pressure less than 90 mmHg

8. The heparin or low molecular allergic patients

9. HIV positive patients

10. Pregnant women or lactational pregnancy women

11. Suspected tuberculosis patients